Genome wide significant locus for Research Diagnostic Criteria Schizoaffective Disorder Bipolar Type. by Green, EK
"This is the pre-peer reviewed version of the following article: [Green EK, Di Florio A, 
Forty L, Gordon-Smith K, Grozeva D, Fraser C, Richards AL, Moran JL, Purcell P, Sklar P, 
Kirov G, Owen MJ, O'Donovan MC, Craddock C, Jones L and Jones IR. Genome-wide 
significant locus for Research Diagnostic Criteria Schizoaffective Disorder Bipolar type 
AMERICAN JOURNAL OF MEDICAL GENETICS PART B: NEUROPSYCHIATRIC GENETICS 
29 AUG 2017, DOI:0.1002/ajmg.b.32572], which has been published in final form at [Link to 
final article using the DOI]. This article may be used for non-commercial purposes in 
accordance with Wiley Terms and Conditions for Self-Archiving." 
 
 
Genome wide significant locus for Research Diagnostic Criteria Schizoaffective Disorder Bipolar 
Type.  
Elaine K Green1, Arianna Di Florio2, 3,  Liz Forty2, Katherine Gordon-Smith4, Detelina Grozeva5, 
Christine Fraser2, Alex Richards2, Jennifer L Moran6, Shaun Purcell6,7, Pamela Sklar6,7 
George Kirov2, Michael J Owen2, Michael C O’Donovan2, Nick Craddock2, Lisa Jones4, Ian R Jones2. 
 
 
1School of Biomedical and Healthcare Sciences, Plymouth University Peninsula Schools of Medicine 
and Dentistry, A413 Portland Square Building, Drake Circus, Plymouth PL4 8AA 
2MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and 
Clinical Neurosciences, Cardiff University, Cardiff, CF24 4HQ, UK 
3Department of Psychiatry, University of North Carolina at Chapel Hill, USA 
4Worcester University 
5Department of Medical Genetics, Cambridge Institute for Medical Research, University of 
Cambridge, Cambridge, UK 
6Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard, 7 Cambridge 
Center, Cambridge, MA 02142, USA 
7Division of Psychiatric Genomics in the Department of Psychiatry, Friedman Brain Institute, and 
Institute for Genomics and Multiscale Biology, Icahn School of Medicine, Mount Sinai, New York, 
NY, USA 
 
 
 
 
 
 
Running Title: GWS association with RDC-SABP. 
 
 
 
 
 
 
 
 
 
Abstract 
Studies have suggested that Research Diagnostic Criteria for Schizoaffective disorder Bipolar type 
(RDC-SABP) might identify a more genetically homogenous subgroup of bipolar disorder. Aiming to 
identify loci associated with RDC-SABP we have performed a replication study using independent 
RDC-SABP cases (n=144) and controls (n=6,559), focusing on the 10 loci that P-value <10-5 for 
RDC-SABP in the Wellcome Trust Case Control Consortium (WTCCC) bipolar disorder sample 
using ‘researcher-specific SNPs’ represented on the custom array, the ImmunoChip. Combining the 
WTCCC and replication datasets by meta-analysis (combined RDC-SABP, n=423, Controls, n=9,494) 
we observed genome wide significance association at one SNP, rs2352974, located within the intron 
of the gene TRAIP on chromosome 3p21.31. This locus did not reach genome wide significance in 
bipolar disorder or schizophrenia large psychiatric genomic consortium datasets, suggesting that it 
may be a relatively specific genetic risk for the bipolar subtype of schizoaffective disorder. 
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Introduction 
In the recent years many successful large scale genome studies have identified genetic susceptibility 
loci, including common, rare and structural variants which confer risk individually to schizophrenia 
(SZ) and bipolar disorder (BD), and a combination of such disorders (PGC-BD, 2011; PGC-SZ, 2014; 
Kirov, 2015; Green et al., 2016). Often such studies of BD and/or SZ include schizoaffective disorder 
as part of the cases sample. Depending on the proportion of cases diagnosed as schizoaffective 
disorder, the inclusion of these individuals may impact on the genetic findings when considering the 
relationship between SZ and BD (Cardno & Owen, 2014).  
 
Research diagnostic criteria for schizoaffective disorder bipolar type are broader than those proposed 
by the World Health Organisation and the American Psychiatric Association and require “some 
temporal overlap” of episodes of mania and psychotic symptoms, “suggestive of schizophrenia”, 
which persist for at least 1 week in the absence of major mood symptomatology (Spitzer et al., 1981, 
Malaspina et al., 2013). Traditional family studies have shown evidence of familial overlap between 
schizoaffective disorder and both SZ and BD, which has been confirmed by Scandinavian population 
registered based studies (Cardno & Owen, 2014). 
 
Genetic studies focusing on individuals rated by research diagnostic criteria as schizoaffective 
disorder bipolar type (RDC-SABP) have previously been performed. Examining the Wellcome Trust 
Case Control Consortium dataset (WTCCC, 2007), we noted that RDC-SABP stood out from other 
subsets of the BD sample as having a significantly excess of strong association signals (P<10-5) and 
hence ‘may be of particular use to for identifying common susceptibility loci GWAS’ (Hamshere et 
al., 2009). In addition, variation at genes encoding GABAA–receptor subunits were associated with 
risk of RDC-SABP and this association was relatively specific to this diagnostic subset, with no 
association to schizophrenia (SZ) or bipolar disorder (BD) (Craddock et al., 2010). This finding was 
replicated in an independent study (Breuer et al., 2011). Finally, polygenic score analysis of RDC-
SABP using schizophrenia derived polygenic scores showed that the polygenic influences on 
schizophrenia had a greater overlap with SABP than those for the remaining bipolar disorder 
individuals (Hamshere et al., 2011).  
 
Aiming to identify loci that are associated with RDC-SABP at statistically stringent levels of 
significance (P-value < 5x10-8) we have genotyped a replication sample using the Illumina Infinium 
HD genotyping array, the ImmunoChip, focusing on the 10 SNPs that reached a P-value threshold of 
< 10-5 in the WTCCC study (Hamshere et al., 2009), and combined the 2 datasets by meta-analysis 
(total RDC-SABP cases, n= 423 and controls, n= 9,494). 
 
 
Materials and Methods 
Samples 
All participants were unrelated, white European, living in the British Isles. The protocols and 
procedures were approved by the relevant ethics review panels where patients were recruited.  
 
Original WTCCC sample set. 
The WTCC bipolar disorder sample and dataset has been previously reported, and as such the sample 
and collection information is not included (WTCCC, 2007). Analysesof subsets of these BD samples, 
including those individuals rated as schizoaffective disorder, bipolar type by Research Diagnostic 
criteria have also been reported (RDC-SABP) (n = 279) (Hamshere et al., 2009; Craddock et al., 2010; 
Green et al., 2010). RDC is a broader definition of SABP, and provide more delineation between 
individuals on the basis of the pattern of mood psychotic symptomatology than rating by DSM-IV 
(APA, 1994; Hamshere et al., 2011,). 
 
Replication sample set 
The independent replication RDC-SABP (n=144) sample set was part of the bipolar disorder sample, 
the BDRN sample (n=1,849). A description of this BD collection has been detailed in Green et al. , 
(2013, 2016). WTCCC2 set was used as the control sample (n = 6,599), and the characteristics and 
recruitment of which have been described in WTCCC 2007. These controls are not screened to 
exclude the presence of psychiatric illness.  
 
Genotyping  
The genotyping was performed using the custom Illumina Infinium HD genotyping array, the 
ImmunoChip. The ImmunoChip BD genotyping study has been previously reported for the 1218 BD 
cases and 2913 controls (Green et al., 2013) but not for the subset of RDC SABP cases. Additional 
samples were genotyped at University College London (UCL) to increase the sample size, including 
631 BD cases (44 RDC-SABP cases) and 3,646 WTCCC2 controls. In total, the replication RDC-
SABP sample consists of 144 RDC-SABP cases and 6,556 WTCCC2 controls, which are independent 
of the original WTCCC GWAS.  
 
This study focuses on 10 SNPs that were included on the ImmunoChip as part of the ‘investigator-
specific SNP selection for replication’ and were independently associated SNPs (r2 < 0.2) with an 
association signal of P<10-5 for RDC-SABP cases against controls in our previous study Hamshere et 
al., 200912. It is worth noting that in this study the Cochran-Armitage trend test of genotype 
distributions with disease was employed, whereas the data presented here was analysed using logistic 
regression of disease state with a genomic inflation factor () of 1.06. As such the P-values and OR’s 
stated may differ slightly from the original publication and the P-values for 2 SNPs are slightly > 10-5. 
 
 
Statistical analysis 
A brief summary of the methodology is described here and more detailed description is available in 
the Supplementary Materials section. The BDRN sample set was genotyped on the ImmunoChip at 
either the Sanger Institute or UCL sequencing facility. The bipolar disorder dataset genotyped at the 
Sanger Institute has been published (Green et al., 2013) and this genotype calling and quality control 
pipeline was implemented for the sample genotyped at UCL. Briefly, the genotypes were called by 
GenoSNP software (Giannoulatou et al., 2008). Genotypes with a call probability of < 85% were 
scored as missing data. The data management and quality control assessment was performed using 
PLINK (v1.07) (Purcell et al., 2007) and a series of shell scripts initially for all BD and control 
samples.  
 
We planned to combine the data genotyped at the two centres. In order to highlight any potential 
‘batch effects’ problems that might prevent the combining of the data, we included 9 identical 
samples from the first centre to be genotyped by UCL. The concordance rate for the 9 samples across 
overlapping SNPs (n=96,184) was very high reaching 99.997%. Thus we felt confident in combining 
the datasets.  
 
From the total BD dataset, 144 RDC-SABP  and controls were extracted (n = 6,556) and quality control analysis 
performed. Principal Component Analysis (PCA) was performed with Eigenstrat on the combined 
sample and any individual outliers that did not cluster near to the HapMap European individuals were 
removed in order to maximise the ethnic homogeneity of our sample (Giannoulatou et al., 2008). The 
genomic inflation factor was calculated using 43K SNPs in relative linkage (α=1). 
 
Meta-analysis 
The RDC-SABP replication dataset was combined with the original RDC-SABP WTCCC (WTCCC 
2007)  dataset by fixed-effects meta-analysis using PLINK (v1.07) (Purcell et al., 2007) to estimate a 
common odds ration weighted by individual study standard errors (SE). 
 
 
 
 
 
 
Results  
An independent replication sample of 144 cases (RDC-SABP) and 6,559 controls SNPs were 
genotyped on the ImmunoChip Illumina array. We have focused on 10 SNPs that showed an 
independent association (r2 < 0.2) signal at P <10-5 for research diagnostic criteria schizoaffective 
disorder, bipolar type against controls in our previous study of the WTCCC dataset previously 
(Hamshere et al., (2009)). We combined our replication data with the WTCCC SNP data by fixed 
effect meta-analysis. SNP, rs2352974, on chromosome 3p21.31 met genome-wide association (P-
value = 4.37x10-8, OR=0.67). This SNP resides within the intronic region of the gene, TRAIP (TRAF 
interacting protein).  
 
A meta-analysis of all SNPs on the ImmunoChip was also performed (data not presented). No 
additional individual SNP was associated at levels that exceed the accepted genome-wide levels of 
significance (P<5x10-8). 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Meta-analysis of WTCCC RDC-SABP (cases n=279, controls n=2 938) and ImmunoChip RDC-SABP data (cases n=144, controls n=9 497). 
 
Abbreviations: A1, allele 1; A2, allele 2; CHR, chromosome; BP, position in base pairs for UCSC Build hg19; WTCCC, Wellcome Trust Case Control 
Consortium; MAF, minor allele frequency; OR, odds ratio; RDC, research diagnostic criteria; SABP, Schizoaffective disorder, bipolar type; Gene, gene 
symbol is followed by the distance between the SNP and the reference sequence gene location. 
The SNPs listed are those with an independent association (r2 < 0.2) signal at P <10-5 for research diagnostic criteria (RDC) schizoaffective disorder, bipolar 
type against controls previously reported by Hamshere et al., 200912 analysed originally using the Cochran-Armitage Trend test, here an updated analysis of 
the WTCCC RDC-SABP dataset has been performed using logistic regression of disease state with a genomic inflation factor (l) of 1.06, as such P-values and 
OR’s may alter slightly from the original publication. Note: rs4786811 is included in the meta-analysis although the MAF is < 0.05 in both cases and controls. 
Rs6414684 was merged with rs4279178*. 
 
Cases 
MAF
Control
s MAF
P-Value OR
Cases 
MAF
Control
s MAF
P OR P OR
rs4027132 2 12037492 G A 0.357 0.459 7.69E-06 0.65 0.486 0.457 0.332 1.12 0.0038 0.81 LPIN1 (70 kb)
rs2352974 3 49890613 T C 0.387 0.499 1.01E-06 0.63 0.413 0.493 0.0084 0.73 4.37E-08 0.67 TRAIP (0 kb)
rs7680321 4 47145107 C T 0.136 0.079 1.02E-05 1.83 0.118 0.090 0.109 1.34 7.03E-06 1.64 GABRB1 (0 kb)
rs4279178* 4 47068580 A G 0.401 0.509 2.96E-06 0.65 0.444 0.482 0.208 0.86 8.24E-06 0.72 GABRB1 (0 kb)
rs13154602 5 76395917 A C 0.363 0.269 3.59E-06 1.58 0.267 0.282 0.574 0.93 6.35E-04 1.31 ZBED3-AS1 (0 kb)
rs1171115 6 84229623 C T 0.357 0.264 9.81E-06 1.52 0.302 0.275 0.308 1.14 3.00E-05 1.38 PRSS35 (0 kb)
rs7990962 13 43399245 G A 0.253 0.173 6.92E-06 1.62 0.163 0.180 0.474 0.89 8.83E-04 1.34 LINC01050|LINC00428  (24.5kb|17.3kb)
rs16942644 15 89612736 A G 0.171 0.102 2.00E-06 1.82 0.135 0.111 0.197 1.25 4.00E-06 1.60 ABHD2 (18.7 kb)
rs4786811 16 6132787 G A 0.041 0.014 1.10E-05 2.98 0.010 0.018 0.368 0.59 2.25E-04 2.32 RBFOX1 (0 kb)
rs4818065 21 41037723 A G 0.272 0.182 6.97E-07 1.69 0.184 0.187 0.905 0.98 5.63E-05 1.42 B3GALT5 (2.9 kb)
Immunochip, RDC_SABP data Meta-analysis
GeneSNP CHR BP A1 A2
WTCCC RDC-SABP data
Discussion 
Combining an independent sample with our previous dataset (Hamshere et al., 2009), we report a 
novel locus reaching genome-wide significant association with schizoaffective disorder bipolar type at 
the intronic SNP rs2352974 (P-Value = 4.37x10-8, OR= 0.67) on chromosome 3p21.31 at TRAIP 
(TRAF interacting protein). In comparison, this loci was not genome-wide significantly associated in 
either the large Psychiatric GWAS Consortium (PGC) bipolar disorder (P=0.39, OR=1.01) or 
schizophrenia (SZ) meta-analysis data (P=0.037, OR=0.98) (PGC-BD, 2011, PGC-SZ, 2014), 
suggesting that it may be a relatively specific genetic risk for bipolar subtype of schizoaffective 
disorder. The gene TRAIP encodes an E3 RING ubiquitin ligase. A recent study has reported that 
mutations within TRAIP are associated with microcephalic primordial dwarfism, and identified TRAIP 
as a component of the DNA damage response replication blocking DNA lesions (Harley et al., 2016).  
 
There is much debate around the clinical usefulness and the nosological status of diagnostic category 
schizoaffective disorder. Discussions include whether schizoaffective disorder is a form of 
schizophrenia, affective disorder, a combination of the two or should be regarded as a separate disease 
entity (Craddock et al., 2009). To add to this there are concerns over the poor reliability of diagnosis 
(Maj et al. 2000;  Santelmann et al., 2015) and apparent low diagnostic stability over time (Schwartz 
et al., 2000;  Laursen et al., 2005). Our findings here, of a susceptibility locus specific (i.e. not 
identified in BD or SZ datasets) for RDC-SABP, combined with our previous genetic findings for 
SABP do further support the notion that SABP is a partly independent diagnostic category, with some 
specific biological characteristics not shared with other phenotypes (Craddock et al., 2009, 2010; 
Hamshere et al., 2009). Larger well phenotypically defined samples, although challenging to collect, 
we envisage will enable the identification of additional risk loci that are specific to SABP, and loci 
that also confer risk to both or either BD and/or SZ. 
 
In summary, within our UK RDC-SABP sample we have identified a genome-wide significantly 
associated locus at an intronic SNP in TRAIP. Our findings further indicate the importance of research 
examining clinical diagnostic phenotypes, which in turn will be ultimately important for clinical 
practice. 
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